Table 2 Clinical characteristics of the LUAD patients used in this study.

From: A novel necroptosis related gene signature and regulatory network for overall survival prediction in lung adenocarcinoma

 

TCGA

GEO

Number of patients

486

440

Age (median, range)

66 (33–88)

64 (33–87)

Gender (%)

  

 Male

264 (54.3)

222 (50.4)

 Female

222 (45.7)

218 (49.5)

Stage (%)

  

 I

262 (53.9)

–

 II

112 (23.1)

–

 III

79 (16.3)

–

 IV

25 (5.1)

–

 Unknown

8 (1.6)

–

T (%)

  

 T1

163 (33.5)

150 (34.1)

 T2

260 (53.6)

251 (57.0)

 T3

41 (8.4)

28 (6.4)

 T4

19 (3.9)

11 (2.5)

 Unknown

3 (0.6)

0

M (%)

  

 M0

333 (68.5)

–

 M1

24 (4.9)

–

 Unknown

129 (26.6)

–

N (%)

  

 N0

312 (64.2)

299 (68)

 N1

90 (18.5)

87 (19.8)

 N2

70 (14.4)

53 (12)

 N3

2 (0.4)

0

 Unknown

12 (2.5)

1 (0.2)

Survival status

  

 OS days (median)

653

1577

 Alive (%)

304 (62.6)

205 (46.6)

 Death (%)

181 (37.4)

235 (53.4)

 Unknown

1 (0.2)

0

Back to article page